Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A

Official title

Clinical Effect of Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A in Patients With Upper Extremity Complex Regional Pain Syndrome: A Prospective Randomized, Double-blind, and Comparative Clinical Trial

Overview

Thoracic sympathetic ganglion block is a percutaneous procedure that paralyzes the action of sympathetic nerves transiently by injecting a local anesthetic around the ganglion. It is performed to diagnose and treat sympathetically maintained pain in phantom limb pain or complex reginal pain syndrome patient. The temperature of the affected arm is often lower than that of the opposite side. As a result of the procedure, the patient may experience sympathetic pain relief, such as coldness, stinging, numbness of the upper extremity. If the procedure does not last long, repetitive block or chemical neurolysis or radiofrequency thermocoagulation for the sympathetic ganglion is performed. However, even though in rare cases, chemical neurolysis is known to cause permanent plexus injury radiofrequency thermocoagulation is known to be less successful than chemical neurolysis because it is difficult to identify and stimulate the exact location of the ganglion. Therefore, it is expected that there will be a benefit to the patients if there is a procedure with long-lasting and avoiding injury. Recently, it has been reported that botulinum toxin (BTX) has been successfully used for the treatment of pain disorders. BTX plays a role with blocking the secretion of acetylcholine from the cholinergic nerve endings. Therefore, the use of BTX is expected to prolong the effect of neural blockade because pre-ganglia sympathetic nerves are cholinergic. It is also known that the action of BTX is not permanent and BTX does not exhibit cytotoxicity or neurotoxicity. Therefore, Botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia. This study would like show whether thoracic sympathetic ganglion block using BTA has a longer duration than conventional local anesthesia by using prospective randomized, double-blind, parallel group, and comparative clinical trials.

Interventions

• Drug Botulinum toxin A
  Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin

Primary outcome measures

• The changes in average pain intensity in 4weeks [Time frame: 4 weeks after procedure]

Secondary outcome measures (10)

• The changes in average pain intensity in 12weeks [Time frame: 12 weeks after procedure]
• The changes in maximum pain intensity [Time frame: 4 and 12 weeks after procedure]
• The changes in pain related to procedure [Time frame: 30 minutes after the procedure]
• The change in the temperature difference [Time frame: 30 minutes, 4 and 12 weeks after the procedure]
• Blood flow velosity [Time frame: 30 minutes, 4 and 12 weeks after the procedure]
• Korean CISS (Cold Intolerance Symptom Severity) Questionnaire [Time frame: 4 and 12 weeks after the procedure]
• Paindetect questionare (PD-Q) [Time frame: 4 and 12 weeks after the procedure]
• Patient satisfaction [Time frame: after procedure]
• Medication change (Opioids) [Time frame: 4 and 12 weeks after the procedure]
• Additional intervention [Time frame: 4 and 12 weeks after the procedure]

Eligibility criteria

Inclusion criteria

• aged 19-80 years
• Diagnosed with a complex regional pain syndrome (type 1 or 2) in unilateral upper extremity
• 11-point numerical-rating-scale (NRS) pain score of 4 or higher in upper extremity
• Temperature increase at diagnostic thoracic sympathetic ganglion block
• Patients taking medication stably (without change in dosage/recipe) for more than 4 weeks prior to administration

Exclusion criteria

• Refusal of the patient
• Vascular disease at upper extremity
• previous thoracic sympathetic neurolysis (thermocoagulation, chemical neurolysis)
• coagulopathy
• systemic infection or local infection at thoracic puncture site
• significant deformity at thoracic spine
• neoplasm
• known allergic reaction with amide type local anesthetics
• cognitive dysfunction (not understanding of numerical-rating-scale)
• known allergic reaction with botulinum toxin
• pregnant or feeding women
• If the patient has participated in another clinical trial within 30 days before screening, or if passed no longer than 5-fold half-life of the clinical trial drug of the participating clinical trial

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06470581 · 2402-117-1516

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗